Warren Buffett
Berkshire Hathaway
Warren Buffett Teva Pharma Industries Ltd ADR stake
total: 135
Berkshire Hathaway TEVA trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2017 Q4
- Held for:
- 16 quarters
- Latest activity:
- 2021 Q4
According to 2026 Q2 report, Warren Buffett doesn't hold any Teva Pharma Industries Ltd ADR (TEVA) shares. To date, the estimated cost basis is nearly $18.36 for "buy" trades and estimated average "sell" price is $9.73. Berkshire Hathaway first purchased TEVA in 2017 Q4, initially acquiring about 18.88M shares. Since the initial investment in Teva Pharma Industries Ltd ADR (TEVA), Berkshire Hathaway has made 4 more transactions.
When did Warren Buffett sell Teva Pharma Industries Ltd ADR (TEVA)?
Warren Buffett sold off the entire Teva Pharma Industries Ltd ADR (TEVA) position in 2021 Q4.
When did Warren Buffett buy Teva Pharma Industries Ltd ADR (TEVA)?
Warren Buffett first invested in Teva Pharma Industries Ltd ADR (TEVA) in 2017 Q4 at the reported quarter-end price of $18.95 per share.
What's the cost basis of Berkshire Hathaway's TEVA stake?
The estimated cost basis for Teva Pharma Industries Ltd ADR (TEVA) stake is around $18.36 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $18.36
- Weighted AVG sell price:
- $9.73
Warren Buffett's historical trades in Teva Pharma Industries Ltd ADR
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$9.74
|
|
-100% (-42,789,295)
|
-0.14%
|
|
2020 Q1
|
0.22%
|
$8.98
|
-1.06% (-460,000)
|
|||
|
2018 Q2
|
0.54%
|
$24.32
|
+6.68% (+2,709,585)
|
|||
|
2018 Q1
|
0.37%
|
$17.09
|
+114.77% (+21,663,989)
|
|||
|
2017 Q4
|
0.19%
|
$18.95
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.